CYCLERION THERAPEUTICS, INC. financials

CYCN CIK 0001755237

Source: EDGAR filings · Built 2026-06-19T02:14:26Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -40.61M -36.52M -74.01M
EBITDA -12.95M -18.48M -54.72M -78.97M
Working Capital 3.73M 3.50M 5.94M 7.19M 44.37M 41.55M
Net Debt -9.88M -50.46M -5.16M
Operating Margin -239.78% -181.40% -6242.42% -1400.18% -3539.42%
Net Margin -170.11% -152.85% -14841.08% -1310.17% -3388.59%
Return on Equity (ROE) -38.83% -34.54% -46.62% -421.72% -107.05% -130.78%
Return on Assets (ROA) -35.33% -31.93% -39.35% -243.81% -87.05% -67.43%
Current Ratio 5.15× 5.83× 3.85× 1.94× 5.00× 3.45×
Debt-to-Equity 0.33× 0.07× 0.83×
Effective Tax Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Conversion Ratio 0.94× 1.42× 4.04× 0.92× 0.71× 0.93×
Accruals Ratio -0.02× 0.13× 1.20× -0.19× -0.26× -0.05×
SBC % of Revenue 21.26% 31.25% 2105.05% 243.81% 652.96%
CapEx Coverage -5216.71× -47.57×
Free Cash Flow Per Share $-18.69 $-0.93 $-2.43

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 2.30M
Revenues 2.07M 2.00M 0 297.00K 3.94M 2.30M
Research and Development Expense 959.00K 286.00K 1.51M 5.98M 37.64M 56.41M
Operating Expenses 7.05M 5.63M 12.95M 18.84M 59.14M 83.56M
Operating Income (Loss) -4.97M -3.63M -12.95M -18.54M -55.20M -81.27M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -3.53M -3.06M -5.26M -44.08M -51.65M -77.80M
Earnings Per Share, Basic $-1.11 $-1.21 $-2.25 $-20.28 $-1.32
Weighted Average Number of Shares Outstanding, Basic 3.18M 2.52M 2.34M 2.17M 39.14M
Earnings Per Share, Diluted $-1.11 $-1.21 $-2.25 $-20.28 $-1.32
Weighted Average Number of Shares Outstanding, Diluted 3.18M 2.52M 2.34M 2.17M 39.14M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 3.24M 3.23M 7.57M 13.38M 53.96M 54.40M
Assets, Current 4.63M 4.22M 8.02M 14.82M 55.46M 58.50M
Assets 9.98M 9.57M 13.37M 18.08M 59.33M 115.38M
Liabilities, Current 900.00K 725.00K 2.09M 7.63M 11.09M 16.95M
Stockholders' Equity Attributable to Parent 9.09M 8.85M 11.29M 10.45M 48.25M 59.49M
Common Stock, Shares, Outstanding 3.82M 2.55M 2.47M 2.18M 43.41M 34.05M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -3.31M -4.33M -21.25M -40.61M -36.52M -72.49M
Payments to Acquire Property, Plant, and Equipment 0 7.00K 1.52M
Net Cash Provided by (Used in) Investing Activities 0 10.40M 0 1.46M 18.00K
Net Cash Provided by (Used in) Financing Activities 3.32M 0 5.02M 29.00K 30.79M 28.09M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CYCN CIK 0001755237), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BCTX

BRIACELL THERAPEUTICS CORP.

IEAG

INFINITE EAGLE ACQUISITION CORP.

SABSW

SAB BIOTHERAPEUTICS, INC.